HOME >> BIOLOGY >> NEWS
Cell Pathways scientists describe mechanism by which SAANDS compounds trigger programmed death in cancerous and precancerous cells

New drug target for inducing apoptosis in abnormal cells published in cancer research

HORSHAM, PA (July 5, 2000) -- Scientists at Cell Pathways, Inc. (Nasdaq: CLPA) and their collaborators have identified a new drug target that may play a key role in cancer cell survival. Exisulind (Aptosyn™) and other compounds in the company's family of selective apoptotic antineoplastic drugs (SAANDs) inhibit this target, cyclic GMP phosphodiesterases of the PDE5 and PDE2 gene families that have been found to be over-expressed in cancerous and precancerous cells of the colon. The inhibition of these target proteins triggers a chain of events which results in the programmed cell death, or apoptosis, of cancerous and precancerous cells, but not normal ones. The drugs have additionally been shown to inhibit the growth of a broad variety of malignant tumor cells beyond colon tumors, in both cell culture and animal models of human cancers.

The new research appears in the July 1 issue of the journal Cancer Research. Cell Pathways scientists and their collaborators at the University of South Alabama College of Medicine, and the University of Colorado authored the paper.

Apoptosis and SAANDs

Apoptosis is the body's response to a normal, orderly sequence of biochemical or physical signals by which damaged or "worn out" cells are eliminated to make way for healthy, new cells. When the mechanism of apoptosis goes awry, cells continue to multiply and grow inappropriately, forming a mass of tissue -- a cancerous tumor. In colon cancer, excessive cell growth occurs as the result of the accumulation of a regulatory protein, beta-catenin, caused by mutations in the adenomatous polyposis coli (APC) gene.

The researchers showed that exisulind and other SAANDs induce apoptosis in colon tumor cells by inhibiting the different forms of cGMP PDE in these cell lines. This results in a sustained increase in cGMP in the cells and the indu
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
4-Jul-2000


Page: 1 2 3

Related biology news :

1. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
2. Pathways of emotion from cortex to peripheral organs
3. Cell Pathways CP461 demonstrates multiple anti-cancer activities
4. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
5. Pitt Researchers Find Way To Block Cellular Growth Pathways And Inhibit Tumor Growth
6. Discovery Of Genetic Pathways May Provide New Ways To Combat Candida Infections
7. DNA lends scientists a hand, revealing new chemical reactions
8. Conference at UH opens doors for new scientists, engineers
9. Wisconsin scientists develop quick botox test
10. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
11. Alaska scientists find Arctic tundra yields surprising carbon loss

Post Your Comments:
(Date:10/28/2014)... Health (NIH) announced awards to expand the Office ... Center for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare ... network, physician scientists at 22 consortia will work ... research and investigate new treatments for patients with ... $29 million in fiscal 2014 funding from NIH. ...
(Date:10/28/2014)... in a novel environment are linked to individual ... experimental study completed at the University of Eastern ... Institute. The study used novel, long-term observations of ... to analyse if behaviours predict the vulnerability to ... enriched hatchery rearing environments. Based on the ...
(Date:10/28/2014)... associated with a lower risk of developing ovarian cancer, ... Anglia (UEA). , Research published today reveals that ... subclasses of dietary flavonoids) significantly decrease their risk of ... death among women. , The research team studied ... and 55 for more than three decades. , ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Fish 'personality' linked to vulnerability to angling 2Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industryā€¯ is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... New York, NY (PRWEB) October 30, 2014 ... investment plan for its ICH Stability Testing and Package ... companies, this investment centers on a dramatic increase in ... larger volume of stability, storage and aging samples to ... first stage of this major capital expenditure has already ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
Cached News: